Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Repligen Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 2 insiders, $5.00M in total
- Insiders trading
- 2
- Net value
- −$5.00M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Repligen Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer | 48,369 | Sep 25, 2026 | 9 |
| Hughes Violetta | CHIEF ACCOUNTING OFFICER | 6,331 | Sep 2, 2026 | 1 |
| Garland Jason K | CFO | 18,829 | Jul 17, 2026 | 4 |
| Muir Glenn P | Director | 40,051 | May 18, 2026 | 3 |
| Dawes Karen A | Director | 92,816 | May 18, 2026 | 2 |
| Barthelemy Nicolas | Director | 5,436 | May 18, 2026 | 1 |
| Madaus Martin D | Director | 6,581 | May 18, 2026 | 1 |
| Eglinton Manner Carrie | Director | 5,461 | May 18, 2026 | 1 |
| Konstantinov Konstantin | Director | 3,889 | May 18, 2026 | 1 |
| Mhatre Rohin | Director | 5,014 | May 18, 2026 | 1 |
| Pax Margaret | Director | 3,011 | May 18, 2026 | 1 |
| Douglass Brian Robb | CHIEF PRODUCT OFFICER | 7,985 | May 8, 2026 | 3 |
| Kuriyel Ralf | Senior VP, R&D | 20,062 | Mar 23, 2026 | 3 |
| Bylund James | Chief Operating Officer | 25,423 | Mar 23, 2026 | 4 |
| Hunt Anthony | Director | 89,062 | Mar 3, 2026 | 4 |
| Gebski Christine | See Remarks | 27,419 | May 15, 2024 | 0 |
| Snodgres Jon | Chief Financial Officer | 37,381 | May 16, 2023 | 0 |
| Ryan Thomas F Jr | Director | 1,457 | Mar 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 (view filing) | Oct 29 | 4 days | Barthelemy NicolasDirector | SSale | −1.65K | $288.20 | −$474.1K | −51.5%1.55K after | 2 lots |
| Sep 15, 2021 (view filing) | Sep 14 | 1 day | Dawes Karen ADirector | SSale | −274 | $294.26 | −$80.6K | −0.3%93.6K after | 5 lots |
| Sep 13, 2021 (view filing) | Sep 9 | 4 days | Hunt AnthonyChief Executive Officer | SSale | −25.0K | $294.75 | −$7.37M | −11.7%189.5K after | 4 lots |
| Sep 2, 2021 (view filing) | Sep 1 | 1 day | Gebski ChristineSee Remarks | SSale | −3.38K | $285.33 | −$963.6K | −9.2%33.3K after | |
| Sep 2, 2021 (view filing) | Sep 1 | 1 day | Dawes Karen ADirector | SSale | −3.46K | $283.91 | −$982.1K | −3.6%93.9K after | 6 lots |
| Sep 2, 2021 (view filing) | Aug 30 | 3 daysLate | Kuriyel RalfSenior VP, R&D | SSale | −4.00K | $282.13 | −$1.13M | −18.7%17.4K after | |
| Aug 19, 2021 (view filing) | Aug 17-18 | 2 days | Dawes Karen ADirector | SSale | −18.9K | $254.16 | −$4.81M | −16.8%94.0K after | 10 lots |
| Aug 19, 2021 (view filing) | Aug 18 | 1 day | Dawes Karen ADirector | SSale | +40 | $262.31 | +$10.5K | 0.0%93.9K after | |
| Aug 5, 2021 (view filing) | Aug 4 | 1 day | Ryan Thomas F JrDirector | SSale | −780 | $250.50 | −$195.4K | −44.5%971 after | |
| Jul 22, 2021 (view filing) | Jul 20 | 2 days | Dawes Karen ADirector | SSale | −4.58K | $202.09 | −$926.6K | −3.9%112.9K after | 4 lots |
| Jul 22, 2021 (view filing) | Jul 13 | 9 days | Dawes Karen ADirector | SSale | −1.52K | $202.23 | −$307.4K | −1.3%117.5K after | Amended4 lots |